european/breast neoplasms

Breast cancer is a serious medical and social problem, and the ultimate goal should be to promote accessible and financially sustainable high standard healthcare interventions and develop patient-oriented strategies for prevention, diagnosis, and treatment. EUROPA DONNA, a nonprofit organization, is

The current status and time trends in breast cancer incidence and survival in the 28 European Union countries (EU-28) is presented here. Rates reported are age adjusted and standardized (ASR). A high incidence and high survival rates were observed in the Northern and Western European countries, with

Europe, despite its division into multiple nations even with a European Union, now enjoys a uniformly high level of cancer detection by virtue of the Europe Against Cancer Program, begun in 1986. The program's aim was reducing cancer mortality by 15% by the year 2000. Its operating arm, the European

The European Guidelines developed for mammography screening have contributed to the general discussion on quality assurance and the important tasks of the health professionals dealing with breast cancer screening. The cooperation of each medical discipline is of utmost importance in order to achieve

BACKGROUND The burden of breast cancer expressed in Disability Adjusted Life Years (DALYs) was compared for six European countries and its sensitivity to different sources of variation examined. METHODS DALYs were calculated using country-specific epidemiological data and European Disability

A European School of Oncology Advisory Group has reviewed the European Code Against Cancer after its initial use over a 6-year period. With minor modifications, the original ten recommendations were found to be adequate, although it was agreed that an Annex was necessary to explain the scientific

An apparent chemotherapeutic dose-response relationship for patients with breast cancer has provided clinicians with the impetus to investigate further the usefulness of dose-intensification strategies in this setting. These approaches have provided promising results: noticeable improvements in

Therapies for breast cancer, melanoma, lung cancer, and neuroendocrine tumors.

Breast cancer (BC) epidemic is recognised now worldwide as the reality of the early twenty-first century. Increasing trends in the postmenopausal BC prevalence, even for the European countries earlier demonstrating relatively stable incidence rates of the disease, are highly alarming for the